Cytarabine

Generic Name
Cytarabine
Brand Names
Cytosar, Vyxeos
Drug Type
Small Molecule
Chemical Formula
C9H13N3O5
CAS Number
147-94-4
Unique Ingredient Identifier
04079A1RDZ
Background

A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)

Indication

For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.

Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.

Associated Conditions
Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia
Associated Therapies
-
Clinical Trials
Related News

Cyclophosphamide and Total Body Irradiation in Treating Patients Who Are Undergoing an Autologous Peripheral Stem Cell Transplant For Chronic Lymphocytic Leukemia

First Posted Date
2006-01-11
Last Posted Date
2018-05-11
Lead Sponsor
German CLL Study Group
Target Recruit Count
169
Registration Number
NCT00275015
Locations
🇩🇪

Charite - Universitaetsmedizin Berlin - Campus Benjamin Franklin, Berlin, Germany

🇩🇪

Robert Roessle Comprehensive Cancer Center at University of Berlin - Charite Campus Buch, Berlin, Germany

🇩🇪

Internistische Praxis - Trier, Trier, Germany

and more 50 locations

Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Phase 2
Completed
Conditions
Leukemia
First Posted Date
2006-01-11
Last Posted Date
2011-02-11
Lead Sponsor
The Cleveland Clinic
Target Recruit Count
40
Registration Number
NCT00274807

Amonafide in Combination With Cytarabine in Secondary AML

Phase 2
Completed
Conditions
Acute Myeloid Leukemia
First Posted Date
2006-01-09
Last Posted Date
2007-02-19
Lead Sponsor
Xanthus Pharmaceuticals, Inc.
Target Recruit Count
80
Registration Number
NCT00273884
Locations
🇺🇸

City of Hope National Medical Center, Duarte, California, United States

🇺🇸

Scripps Cancer Center, San Diego, California, United States

🇺🇸

UCLA Medical Center, Los Angeles, California, United States

and more 18 locations

Safety and Efficacy of Unrelated Cord Blood Transplantation for Adult Patients With Hematologic Malignancies

First Posted Date
2005-12-29
Last Posted Date
2012-04-06
Lead Sponsor
Keio University
Target Recruit Count
33
Registration Number
NCT00270881
Locations
🇯🇵

Keio University School of Medicine, Tokyo, Japan

Imatinib Mesylate, Daunorubicin, and Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia

Phase 1
Completed
Conditions
Leukemia
First Posted Date
2005-12-22
Last Posted Date
2013-02-15
Lead Sponsor
The Cleveland Clinic
Target Recruit Count
21
Registration Number
NCT00268229
Locations
🇺🇸

Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States

Biology and Treatment Strategy of AML in Its Subgroups: Multicenter Randomized Trial by the German Acute Myeloid Leukemia Cooperative Group (AMLCG)

Phase 3
Completed
Conditions
Acute Myeloid Leukemia
First Posted Date
2005-12-15
Last Posted Date
2012-10-26
Lead Sponsor
University Hospital Muenster
Target Recruit Count
3500
Registration Number
NCT00266136
Locations
🇩🇪

University of Muenster, Medical Center, Department of Medicine, Hematology and Oncology, Muenster, Germany

Cladribine, Cytarabine, and Imatinib Mesylate in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Blastic Phase Chronic Myelogenous Leukemia

Phase 1
Completed
Conditions
Leukemia
First Posted Date
2005-11-24
Last Posted Date
2013-10-16
Lead Sponsor
University of Rochester
Target Recruit Count
18
Registration Number
NCT00258271
Locations
🇺🇸

James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester, New York, United States

Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma

First Posted Date
2005-10-27
Last Posted Date
2015-03-26
Lead Sponsor
Barbara Ann Karmanos Cancer Institute
Target Recruit Count
15
Registration Number
NCT00244946
Locations
🇺🇸

Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Fludeoxyglucose F 18 Positron Emission Tomography in Predicting Risk of Relapse in Patients With Non-Hodgkin's Lymphoma Who Are Undergoing Combination Chemotherapy With or Without Autologous Stem Cell or Bone Marrow Transplant

Phase 2
Completed
Conditions
Lymphoma
First Posted Date
2005-10-13
Last Posted Date
2017-11-06
Lead Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Target Recruit Count
59
Registration Number
NCT00238368
Locations
🇺🇸

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

Safety and Efficacy of Imatinib in Combination With High Dose Chemotherapy for Acute Phase Chronic Myelogenous Patients

Phase 1
Terminated
Conditions
Chronic Myeloid Leukemia
First Posted Date
2005-09-22
Last Posted Date
2005-11-28
Lead Sponsor
Poitiers University Hospital
Target Recruit Count
30
Registration Number
NCT00219765
Locations
🇫🇷

University Hospital, Poitiers, France

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy